title: Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.
authors.forename: P H
authors.initials: PH
authors.lastname: Cottu
authors.forename: J
authors.initials: J
authors.lastname: Asselah
authors.forename: M
authors.initials: M
authors.lastname: Lae
authors.forename: J-Y
authors.initials: JY
authors.lastname: Pierga
authors.forename: V
authors.initials: V
authors.lastname: Diéras
authors.forename: L
authors.initials: L
authors.lastname: Mignot
authors.forename: B
authors.initials: B
authors.lastname: Sigal-Zafrani
authors.forename: A
authors.initials: A
authors.lastname: Vincent-Salomon
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000235:genetics* / Q000628:therapy*; D000069287:Capecitabine; D044584:Carcinoma, Ductal / Q000235:genetics* / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics / Q000556:secondary; D008875:Middle Aged; D012074:Remission Induction; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D000068878:Trastuzumab; D005472:Fluorouracil